Worst of Barrier Reverse Convertible on NESTLE, NOVARTIS and ROCHE

Coupon 10% in fine - 1 Year - American Barrier at 80% - CHF

Details Redemption
Issuer EFG Financial Products
Guarantor EFG International Collateral-Secured Product On 24.03.2010 Client pays CHF 1000 (Denomination)
Rating: Fitch A No issuer risk
Underlying NESTLE SA-REG NOVARTIS AG-REG ROCHE HOLDING AG-
GENUSSCHEIN On 17.03.2011 Client receiv es a Coupon of 10% in fine plus:
Bbg Ticker NESN VX Equity NOVN VX Equity ROG VX Equity
Strike Level (100%) CHF 53.8 CHF 58.55 CHF 179 Scenario 1: if the Underlyings have never traded at or below the Barrier level
Barrier Level (80%) CHF 43.04 CHF 46.84 CHF 143.2
The Investor will receive a Cash Settlement in the Settlement Currency equal to:
Initial Fixing Date 10.03.2010 Denomination
Payment Date 24.03.2010
Scenario 2: if one or more Underlyings traded at least once at or below the Barrier
Valuation Date 10.03.2011
Maturity Date 17.03.2011 a. If the Final Fixing Level of the Underlying with the Worst Performance is above
EU Saving Tax Option Premium Component 9.37% p.a. the respective Strike Level, the Investor will receive a Cash Settlement in the
Interest Component 0.63% p.a. Settlement Currency equal to: Denomination
Details Cash Settlement American Barrier b. If the Final Fixing Level of the Underlying with the Worst Performance is at or
ISIN CH0111080187 below the Strike Level, the Investor will receive a Cash Settlement in the
Valoren 11108018 Settlement Currency equal to: Denomination x (100% + Performance of the
SIX Symbol To Be Determined Worst Performing Underlying)

Characteristics
Underlying____________________________________________________________________________________________________________________________________________________________________
- Nestle SA is a multinational packaged food company that manufactures and markets a wide range of food products. The Company's product lines include milk, chocolate,
confectionery, bottled water, coffee, creamer, food seasoning and pet foods.
- Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company produces pharmaceuticals for cardiovascular, respiratory and infectious diseases;
oncology, neuroscience, transplantation, ophthalmics, dermatology, gastrointestinal and urinary conditions, and arthritis; vaccines and diagnostics; generics; and over-the-counter,
vision, and animal health products.

- Roche Holding AG develops and manufactures pharmaceutical and diagnostic products. The Company produces prescription drugs in the areas of cardiovascular, infectious,
autoimmune, and respiratory diseases, dermatology, metabolic disorders, oncology, transplantation, and the central nervous system.

Opportunities_________________________________________________________________ Risks______________________________________________________________________________
1. A guaranteed Coupon of 10% in fine 1. Maximum return of 10% in fine
2. Protection against 20% drop in Underlying's price 2. Exposure to v olatility changes
3. Low er v olatility than direct equity exposure
4. Secondary market as liquid as a share
5. Optimization of EU Tax components
6. COSI Product: the inv estor does not bear issuer's Credit risk
Best case scenario____________________________________________________________ Worst case scenario_______________________________________________________________
One or all the Underlyings traded below the Barrier Lev el and on the Final
None of the Underlyings has ev er traded below the Barrier Lev el
Fixing Date close under the Strike
Redemption: Denomination x (100% + Performance of the Worst performing
Redemption: Denomination + 10% in fine
Underlying) + Coupon of 10% in fine (With Negativ e Performance)

Historical Chart
120%
importer depuis la deuxiemeNestle
feuille
Redemption: Denomination + Coupon of 10% in fine
Novartis
110%
Roche
Strike Level at 100%
100%

90%
20% Protection

80%
Barrier Level at 80%

70%
Redemption: Performance of the Worst Performing Underlying
+ Coupon of 10% in fine

60%
Jan-08 Mar-08 May-08 Jul-08 Sep-08 Nov-08 Jan-09 Mar-09 May-09 Jul-09 Sep-09 Nov-09 Jan-10

Contacts
Filippo Colombo Christ ophe Spanier Nathanael Gabay
Bruno Frat eschi +41 58 800 10 45 Sofiane Zaiem
Stanislas Perromat +41 22 918 70 05
Alejandro Pou Cuturi Live prices at www.efgfp.com
+377 93 15 11 66

This publication serves only fo r info rmatio n purpo ses and is no t research; it co nstitutes neither a reco mmendatio n for the purchase o f financial instruments nor an o ffer o r an invitatio n fo r an o ffer. No respo nsibility is taken fo r the co rrectness o f this info rmatio n. The financial instruments
mentio ned in this do cument are derivative instruments. They do no t qualify as units o f a co llective investment scheme pursuant to art. 7 et seqq. o f the Swiss Federal A ct o n Co llective Investment Schemes (CISA ) and are therefo re neither registered no r supervised by the Swiss Financial M arket
Superviso ry Autho rity FINM A . Investo rs bear the credit risk o f the issuer/guaranto r. B efo re investing in derivative instruments, Investo rs are highly reco mmended to ask their financial adviso r fo r advice specifically fo cused on the Investo r´s financial situatio n; the informatio n co ntained in this
do cument do es no t substitute such advice. This publicatio n do es no t co nstitute a simplified pro spectus pursuant to art. 5 CISA , o r a listing pro spectus pursuant to art. 652a o r 1156 o f the Swiss Co de o f Obligatio ns. The relevant pro duct do cumentatio n can be o btained directly at EFG Financial
P roducts A G: Tel. +41(0)58 800 1111, Fax +41(0)58 800 1010, o r via e-mail: termsheet@efgfp.co m. Selling restrictions apply for Euro pe, Ho ng Ko ng, Singapo re, the USA, US perso ns, and the United Kingdo m (the issuance is subject to Swiss
law). The Underlyings´ perfo rmance in the past do es no t co nstitute a guarantee fo r their future perfo rmance. The financial pro ducts' value is subject to market fluctuatio n, what can lead to a partial o r to tal lo ss o f the invested capital. The purchase o f the financial pro ducts triggers co sts and fees.
EFG Financial P ro ducts AG and/o r ano ther related co mpany may o perate as market maker fo r the financial products, may trade as principal, and may co nclude hedging transactio ns. Such activity may influence the market price, the price mo vement, o r the liquidity o f the financial pro ducts. © EFG
Financial P ro ducts A G All rights reserved.